Ce diaporama a bien été signalé.
Nous utilisons votre profil LinkedIn et vos données d’activité pour vous proposer des publicités personnalisées et pertinentes. Vous pouvez changer vos préférences de publicités à tout moment.

A groundbreaking 3D cell culture technology for HCS: BIOMIMESYS hydroscaffold

203 vues

Publié le

Most potential drug candidates (90%) fail within the clinical trials, mainly because of lack of efficacy.
What if the pharmaceutical industry uses predictive human in vitro models in early drug discovery ?

Publié dans : Business
  • Soyez le premier à commenter

  • Soyez le premier à aimer ceci

A groundbreaking 3D cell culture technology for HCS: BIOMIMESYS hydroscaffold

  1. 1. Introduction What is the extracellular matrix (ECM)? Conclusion and perspectives Nathalie Maubon1*, Marie Lesaffre1, Véronique De Conto1, Elodie Vandenhaute1, Zied Souguir1 A groundbreaking 3D cell culture technology for HCS: BIOMIMESYS hydroscaffold 1 HCS pharma, 250 rue Salvador Allende, Biocentre Fleming Bâtiment A, 59120 Loos, FRANCE Results What is hydroscaffold? To properly mimic human tissues, the ECM should be included in in vitro models. BIOMIMESY properly reproduces the ECM, and is available: • glycosaminoglycans (essentially Hyaluronic Acid, HA) • structural (mainly collagens) • adhesion proteins (laminins, fibronectin)  ECM properties are crucial in maintaining organ’s homeostasis! BIOMIMESYS® = HA grafted with other ECM components (collagens, adhesion peptides…), which composition and physico-chemical properties are tailored to mimic the ECM of each organ/tissue. References We are working hard to develop new BIOMIMESYS® products: Liver Decellularized human adipose tissue IN VIVO Hyaluronic sheets Collagen fibers IN VITRO - Primary human white adipocytes in Adipored™  Promoted accumulation of triglycerides along time The ECM has diverse and crucial roles, in health and disease: ECM = ECM composition & physicochemical properties depend on the organ/tissue : Most potential drug candidates (90%) fail within the clinical trials, mainly because of lack of efficacy. Source: AstraZeneca What if the pharmaceutical industry uses predictive human in vitro models in early drug discovery ? IN VITRO Hyaluronic sheets Collagen fibers IN VIVO Decellularized human liver  BIOMIMESYS® structure is the same as the in vivo ECM (decellularized human tissue)  BIOMIMESYS® helps the long-term maintenance of cellular differentiation, compared to 2D - Primary human hepatocytes in  Maintained differentiation of hepatocytes - Human neuronal cells in  Formation of ‘mini-brains’  BIOMIMESYS® promotes the maintenance of cellular functionality - Lipogenesis model in - Cholestasis model in RA, retinoic acid  Higher lipogenesis in BIOMIMESYS, and 30% lipogenesis inhibition by RA  Induction of cholestasis by CPZ [chlorpromazine (CPZ)] - Immune & cancer cells in Luhmes cells Comparison of BIOMIMESYS® to other 3D systems  BIOMIMESYS® allows coculture and live cell imaging Human cancer cell line (HCT116) + primary human macrophages NEW 384-well plates: Liver pathology: Louis et al., 2017. A biomimetic hydrogel functionalized with adipose ECM components as a microenvironment for the 3D culture of human and murine adipocytes. Biotechnol Bioeng, 114(8):1813-1824. For more information, go to : biomimesys.com or hcs-pharma.com or scan this QR-code 1* : nathalie.maubon@hcs-pharma.com

×